There is a strong association between increased blood concentrationsof low-density lipoprotein (LDL) and severity of coronary atherosclerosis. Multiple mechanisms affect hypercholesterolemia, e.g., diet, aging, hormones, and genetics. LDL receptors apparently are also impor- In the discussion to follow, current concepts of LDL metabolism and the role of LDL in atherogenesis will be reviewed.
VLDL particles are responsible for transporting triglyceride fatty acids from the liver to peripheral tissues for utilization.
When
VLDLs enter capifiaries, they come into contact with lipeprotein lipase (LPL), an enzyme that hydrolyzes the triglycerides and releases fatty acids for tissue utilization.
VLDL carry two other groups of apelipeprotein, the ape Cs and ape Es. Ape CII is a cofactor for the activation of LPL. Ape E plays a role in the disposition of VLDL. After most of the triglycerides are removed from VLDL, a residual particle, called a VLDL remnant, remains in the circulation.
Some of the circulating VLDL remnants are removed directly by the liver in a process mediated by ape E. Cell surfaces of liver cells contain receptors that recognize and bind to the ape E on remnants; the remnant lipeprotein is then internalized and removed from the circulation.
However, another fraction of VLDL remnants remains in the circulation and is converted to LDL. Thus the proportion of VLDL remnants converted to LDL greatly influences the concentration of serum LDL. Usually, about twothirds of remnants is taken up by the liver, and onethird goes to LDL. If a greater fraction of VLDL is transformed to LDL, the concentrations of the latter will rise. More VLDL also will go to LDL if the number of VLDL particles secreted by the liver increases. Factors determining rates of hepatic secretion of VLDL particles are currently the subject of intense investigation.
Another factor affecting LDL concentrations is the fractional removal rate of LDL from the circulation. This rate is determined in large part by the availability of cell-surface receptors for LDL (LDL receptors), particularly on liver cells. At least 75% of circulating LDL is removed via the liver, with the remainder going to other tissues (6) . Most of LDL is cleared by way of LDL receptors, although a smaller fraction is removed by nonreceptor pathways. The latter mechanism probably represents bulk-phase endocytosis. Steady-state concentrations of LDL thus depend on rates of conversion of VLDL to LDL and the fractional clearance rate for LDL.
EvidenceThat LDL Is Atherogenic
The NCEP has designated LDL as the major atherogenie lipeprotein and the primary target of cholesterollowering therapy (1). Let us therefore ask: What is the evidence to suppert this claim? In fact, several lines of evidence underlie the conclusion that LDL is a major of cause of atherosclerosis: studies in laboratory animals, epidemiologic evidence, genetic hypercholesterolemias, 
How LDL ProducesAtherosclerosis
Although the multiple lines of evidence discussed above provide almost incontrovertible evidence that high concentrations of LDL produce atherosclerosis, the precise mechanism(s) whereby this occurs is not fully understood.
In recent years a great interest has developed as to the nature of such mechanisms.
Several possibilities exist and, in fact, multiple mechanisms may be involved (Fig. 1) . The various theories currently under investigation include the following: 1) Endothelial damage.
One theory holds that endothelial damage is the first step in atherogenesis This cholesterol is present both between and within cells (10). The next stage of atherosclerosis is the fibrous plaque, which appears to arise out of the fatty streak. The potential role of LDL in the various stages of atherogenesis therefore can be considered. Intercellular accumulation of cholesterol. The deposition of cholesterol in the intracellular matrix of the arterial wall could result from the interaction of LDL with proteoglycans and elastin. Because the apolipeprotein of LDL, ape B-100, seemingly has a high affinity for proteoglycans (25) (26) (27) and elastin (28) (29) (30) (31) , these interactions could trap and retain LDL within the arterial wall. Not only might this process lead to deposition of cholesterol in the intercellular matrix of the intima, it could also render LDL susceptible to cellular engulfment followed by intracellular deposition of cholesterol. To understand the role of LDL in atherogenesis, one must keep in mind the two-stage process whereby atherosclerotic plaques develop (Fig. 2) . LDL appears to be necessary for the formation of the fatty streak; and, without the formation of this lesion, there will be no progression to the fibrous plaque. Evidence is growing that other CHD risk factors (smoking, hypertension, diabetes) act mainly to promote conversion of fatty streaks into fibrous plaques (39) (44) (45) (46) .
In contrast to the other risk factors, low concentrations of HDL, in conjunction with high concentrations of LDL, may promote the formation of the fatty streak. This may be related to the ability of HDL to promote reverse cholesterol transport, i.e., to remove excess cholesterol from the surface of cells (47); or, a high concentration of HDL may exert its protective effect against the development of CHD through interaction with LDL. This may explain why low HDL cholesterol concentrations are a major risk factor for CHD, but only when LDL concentrations are relatively high .
Clinical Approach to High Blood Cholesterol
In the discussion to follow, the term "hypercholesterolemia" will be used synonymously with high concentrations of LDL cholesterol. In overall populations, LDL cholesterol concentrations are highly correlated with total cholesterol concentrations, although in individual patients this is not necessarily true. A classification of serum cholesterol concentrations, based on NCEP recommendations (1), is shown in Fig. 3 Given that a borderline-high cholesterol (mild hypercholesterolemia)
is an important risk factor, we might ask about its causes. What causes the concentrations to rise into this range? Fig. 4 Management. The management of borderline-high cholesterol concentrations flows logically from the causes. First on the list is to reduce the intakes of saturated fat and cholesterol. This can be achieved in large part by a reduction in the intake of animal fats: whole milk and its high-fat products and animal fats. Egg consumption also should be reduced. Animal products need not be eliminated from the diet, but choices should be restricted to low-fat commodities.
Animal fats can be replaced by vegetable oils, particularly those high in monounsaturated fatty acids (e.g., olive oil and canola oil) (62). Weight reduction in obese patients is necessary to further reduce cholesterol values. Finally, estrogen replacement therapy can be considered for women with mild hypercholesterolemia, especially if their LDL cholesterol concentrations are high. In most people having borderline-high cholesterol, espousing these measures desirable range.
High Serum Cholesterol
NCEP guidelines (1) rank total cholesterol concentrations >240 mg'dL as "high." As the concentration increases progressively beyond 240 mg/dL, the risk for CHD rises correspondingly.
About 20% of all American adults have a high serum cholesterol concentration, increasing to 25-30% in older Americans. For practical purposes, I will divide the high cholesterol category into "moderately high" (240-320 mg/dL) and "severely elevated" (>320 mg/dL), values corresponding to LDL-cholesterol of 160-220 and >220 mg/dL, respectively.
In the absence of secondary causes, the former range is designated "primary moderate hypercholesterolemia"; the latter, "primary severe hypercholesterolemia." These two categories will be discussed separately.
Primary moderate hypercholesterolemia. showed that most patients with severe hypercholesterolemia have at least two of the defects shown in Fig. 5 , added to an underlying borderline-high cholesterol concentration.
This finding conforms to the pelygenic nature of many cases of severe hypercholesterolemia.
Of-
ten, the concentrations of LDL cholesterol are increased so severely that two drugs in combination are required to produce an adequate decrease of LDL cholesterol.
Perhaps the most desirable drug combination is a bile acid sequestrant plus a statin: This combination has the potential to reduce LDL cholesterol concentrations by as much as 50% (68).
